Biovica publishes a summary of study-results in breast cancer with DiviTum®

Biovica has a comprehensive study program with DiviTum® to demonstrate the clinical value for cancer patients. Biovica has published a summary brochure in order to share knowledge about results achieved so far with DiviTum® to researchers, oncologists and other stakeholders. The summary describes all clinical studies presented where DiviTum® is used to evaluate response to breast cancer treatment.

2021-04-11T00:50:30+02:00May 22nd, 2019 09:45|News|

Biovica attends ASCO in Chicago

Uppsala, Sweden, May 8, 2019: Biovica will participate in the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago May 31-June 4, 2019

2021-04-11T00:50:30+02:00May 8th, 2019 11:09|News|

Kommuniké från extra bolagsstämman i Biovica

Extra bolagsstämman i Biovica International AB (publ) ("Biovica" eller "Bolaget") hölls idag den 2 maj 2019 varvid aktieägarna fattade följande beslut. Beslut om att godkänna styrelsens beslut om nyemission av B-aktier med avvikelse från aktieägarnas företrädesrätt

2021-04-11T00:50:26+02:00May 2nd, 2019 13:30|Regulatory|

Announcement from Biovica’s extra general meeting

The extra general meeting ("EGM") of Biovica International AB (publ) ("Biovica" or the "Company") was held today on 2 May 2019 and the following resolutions were passed by the meeting. Resolution regarding approval of the board of directors' resolution to issue new class B shares with deviation from the shareholders' preferential rights

2021-04-11T00:50:30+02:00May 2nd, 2019 13:30|Regulatory|